Maccura Biotechnology Co Ltd (300463) - Net Assets
Based on the latest financial reports, Maccura Biotechnology Co Ltd (300463) has net assets worth CN¥6.31 Billion CNY (≈ $923.69 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥7.99 Billion ≈ $1.17 Billion USD) and total liabilities (CN¥1.68 Billion ≈ $245.61 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 300463 tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥6.31 Billion |
| % of Total Assets | 79.0% |
| Annual Growth Rate | 23.96% |
| 5-Year Change | 38.84% |
| 10-Year Change | 176.16% |
| Growth Volatility | 37.54 |
Maccura Biotechnology Co Ltd - Net Assets Trend (2011–2025)
This chart illustrates how Maccura Biotechnology Co Ltd's net assets have evolved over time, based on quarterly financial data. See 300463 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Maccura Biotechnology Co Ltd (2011–2025)
The table below shows the annual net assets of Maccura Biotechnology Co Ltd from 2011 to 2025. For live valuation and market cap data, see 300463 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥6.31 Billion ≈ $922.72 Million |
-1.84% |
| 2024-12-31 | CN¥6.42 Billion ≈ $939.98 Million |
-2.84% |
| 2023-12-31 | CN¥6.61 Billion ≈ $967.46 Million |
+1.25% |
| 2022-12-31 | CN¥6.53 Billion ≈ $955.50 Million |
+43.77% |
| 2021-12-31 | CN¥4.54 Billion ≈ $664.60 Million |
+13.39% |
| 2020-12-31 | CN¥4.01 Billion ≈ $586.12 Million |
+20.37% |
| 2019-12-31 | CN¥3.33 Billion ≈ $486.94 Million |
+16.15% |
| 2018-12-31 | CN¥2.86 Billion ≈ $419.24 Million |
+9.64% |
| 2017-12-31 | CN¥2.61 Billion ≈ $382.37 Million |
+14.44% |
| 2016-12-31 | CN¥2.28 Billion ≈ $334.12 Million |
+14.14% |
| 2015-12-31 | CN¥2.00 Billion ≈ $292.73 Million |
+152.57% |
| 2014-12-31 | CN¥792.05 Million ≈ $115.90 Million |
+31.03% |
| 2013-12-31 | CN¥604.48 Million ≈ $88.46 Million |
+36.46% |
| 2012-12-31 | CN¥442.98 Million ≈ $64.82 Million |
+42.09% |
| 2011-12-31 | CN¥311.77 Million ≈ $45.62 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Maccura Biotechnology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1574.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥3.77 Billion | 60.14% |
| Other Components | CN¥2.50 Billion | 39.86% |
| Total Equity | CN¥6.28 Billion | 100.00% |
Maccura Biotechnology Co Ltd Competitors by Market Cap
The table below lists competitors of Maccura Biotechnology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai Pudong Road & Bridge Construction Co Ltd
SHG:600284
|
$742.55 Million |
|
Ridley Corporation Ltd
AU:RIC
|
$742.65 Million |
|
Weihai Guangtai Airport Equipment Co Ltd
SHE:002111
|
$742.69 Million |
|
Shandong Xinneng Taishan Power Generation Co Ltd
SHE:000720
|
$742.84 Million |
|
Ferrari Group PLC
AS:FERGR
|
$742.27 Million |
|
Hunan Jiudian Pharmaceutical Co Ltd
SHE:300705
|
$742.22 Million |
|
PennantPark Floating Rate Capital Ltd
NYSE:PFLT
|
$742.15 Million |
|
Southern Missouri Bancorp Inc
NASDAQ:SMBC
|
$742.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Maccura Biotechnology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,369,056,728 to 6,275,633,895, a change of -93,422,833 (-1.5%).
- Net loss of 35,826,986 reduced equity.
- Dividend payments of 83,740,015 reduced retained earnings.
- Other comprehensive income decreased equity by 322,667,679.
- Other factors increased equity by 348,811,847.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-35.83 Million | -0.57% |
| Dividends Paid | CN¥83.74 Million | -1.33% |
| Other Comprehensive Income | CN¥-322.67 Million | -5.14% |
| Other Changes | CN¥348.81 Million | +5.56% |
| Total Change | CN¥- | -1.47% |
Book Value vs Market Value Analysis
This analysis compares Maccura Biotechnology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.81x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 12.00x to 0.81x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.70 | CN¥8.39 | x |
| 2012-12-31 | CN¥1.00 | CN¥8.39 | x |
| 2013-12-31 | CN¥1.36 | CN¥8.39 | x |
| 2014-12-31 | CN¥1.77 | CN¥8.39 | x |
| 2015-12-31 | CN¥3.58 | CN¥8.39 | x |
| 2016-12-31 | CN¥4.03 | CN¥8.39 | x |
| 2017-12-31 | CN¥4.48 | CN¥8.39 | x |
| 2018-12-31 | CN¥4.87 | CN¥8.39 | x |
| 2019-12-31 | CN¥5.61 | CN¥8.39 | x |
| 2020-12-31 | CN¥6.81 | CN¥8.39 | x |
| 2021-12-31 | CN¥7.72 | CN¥8.39 | x |
| 2022-12-31 | CN¥10.35 | CN¥8.39 | x |
| 2023-12-31 | CN¥10.42 | CN¥8.39 | x |
| 2024-12-31 | CN¥10.40 | CN¥8.39 | x |
| 2025-12-31 | CN¥10.38 | CN¥8.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Maccura Biotechnology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.57%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.65%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.27x
- Recent ROE (-0.57%) is below the historical average (18.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 38.62% | 23.10% | 1.03x | 1.62x | CN¥89.24 Million |
| 2012 | 35.71% | 26.10% | 0.96x | 1.42x | CN¥113.91 Million |
| 2013 | 31.95% | 24.78% | 0.93x | 1.38x | CN¥132.71 Million |
| 2014 | 28.56% | 24.20% | 0.77x | 1.54x | CN¥147.01 Million |
| 2015 | 12.58% | 23.57% | 0.45x | 1.19x | CN¥51.53 Million |
| 2016 | 13.91% | 20.96% | 0.55x | 1.20x | CN¥87.68 Million |
| 2017 | 14.96% | 18.99% | 0.55x | 1.43x | CN¥124.06 Million |
| 2018 | 16.51% | 16.57% | 0.59x | 1.69x | CN¥175.40 Million |
| 2019 | 16.80% | 16.30% | 0.59x | 1.76x | CN¥212.62 Million |
| 2020 | 20.91% | 21.43% | 0.58x | 1.68x | CN¥414.25 Million |
| 2021 | 22.25% | 24.03% | 0.61x | 1.53x | CN¥526.75 Million |
| 2022 | 11.25% | 19.63% | 0.44x | 1.30x | CN¥78.85 Million |
| 2023 | 4.90% | 10.80% | 0.36x | 1.27x | CN¥-325.86 Million |
| 2024 | 1.99% | 4.98% | 0.32x | 1.25x | CN¥-510.10 Million |
| 2025 | -0.57% | -1.65% | 0.27x | 1.27x | CN¥-663.39 Million |
Industry Comparison
This section compares Maccura Biotechnology Co Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,027,998,176
- Average return on equity (ROE) among peers: 24.61%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Maccura Biotechnology Co Ltd (300463) | CN¥6.31 Billion | 38.62% | 0.27x | $742.36 Million |
| Berry Genomics Co Ltd (000710) | $41.15 Million | 36.01% | 2.32x | $406.61 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $110.32 Million | 15.56% | 0.62x | $1.67 Billion |
| Hangzhou Tigermed Consulting (300347) | $146.03 Million | 32.73% | 0.28x | $4.33 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $385.67 Million | 35.53% | 0.12x | $972.92 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $2.93 Billion | 8.79% | 0.26x | $470.71 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $2.53 Billion | 14.31% | 0.13x | $505.18 Million |
| BGI Genomics Co Ltd (300676) | $150.37 Million | 54.36% | 5.67x | $2.17 Billion |
| Amoy Diagnostics Co Ltd (300685) | $1.70 Billion | 15.35% | 0.14x | $959.68 Million |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.25 Billion | 8.85% | 0.18x | $507.55 Million |
About Maccura Biotechnology Co Ltd
Maccura Biotechnology Co.Ltd engages in the research, development, manufacture, and sale of in vitro diagnostic products; and provides related services for medical laboratories in China and internationally. The company offers laboratory automation solutions, such as hematology analysis workstations; immunoassay products, such as chemiluminescence analyzers and reagents; molecular products, such a… Read more